Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Joel W Neal, MD"'
Autor:
Maliazurina B Saad, PhD, Lingzhi Hong, MD, Muhammad Aminu, MD, Natalie I Vokes, MD, Pingjun Chen, PhD, Morteza Salehjahromi, PhD, Kang Qin, MD, Sheeba J Sujit, PhD, Xuetao Lu, PhD, Elliana Young, MS, Qasem Al-Tashi, PhD, Rizwan Qureshi, PhD, Carol C Wu, ProfMD, Brett W Carter, ProfMD, Steven H Lin, ProfMD, Percy P Lee, ProfMD, Saumil Gandhi, MD, Joe Y Chang, ProfMD, Ruijiang Li, PhD, Michael F Gensheimer, MD, Heather A Wakelee, ProfMD, Joel W Neal, MD, Hyun-Sung Lee, MD, Chao Cheng, PhD, Vamsidhar Velcheti, ProfMD, Yanyan Lou, MD, Milena Petranovic, MD, Waree Rinsurongkawong, PhD, Xiuning Le, MD, Vadeerat Rinsurongkawong, PhD, Amy Spelman, PhD, Yasir Y Elamin, MD, Marcelo V Negrao, MD, Ferdinandos Skoulidis, MD, Carl M Gay, MD, Tina Cascone, MD, Mara B Antonoff, MD, Boris Sepesi, MD, Jeff Lewis, BS, Ignacio I Wistuba, ProfMD, John D Hazle, ProfPhD, Caroline Chung, MD, David Jaffray, ProfPhD, Don L Gibbons, ProfMD, Ara Vaporciyan, ProfMD, J Jack Lee, ProfPhD, John V Heymach, ProfMD, Jianjun Zhang, MD, Jia Wu, PhD
Publikováno v:
The Lancet: Digital Health, Vol 5, Iss 7, Pp e404-e420 (2023)
Summary: Background: Only around 20–30% of patients with non-small-cell lung cancer (NCSLC) have durable benefit from immune-checkpoint inhibitors. Although tissue-based biomarkers (eg, PD-L1) are limited by suboptimal performance, tissue availabil
Externí odkaz:
https://doaj.org/article/0a63dfd25a6f4694ab5c9c636dd7ce6b
Autor:
Joel W. Neal, MD, PhD, Armando Santoro, MD, Maria Gonzalez-Cao, MD, PhD, Farah Louise Lim, MRCP, MD, Bruno Fang, MD, Ryan D. Gentzler, MD, MS, Jerome Goldschmidt, MD, Polina Khrizman, MD, Claudia Proto, MD, Shiven Patel, MD, MBA, FACP, Sonam Puri, MD, Stephen V. Liu, MD, Erminia Massarelli, MD, PhD, MS, Denise Williamson, MPH, Martin Schwickart, PhD, Christian Scheffold, MD, PhD, Svetlana Andrianova, MD, MPH, Enriqueta Felip, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 10, Pp 100666- (2024)
Introduction: We evaluated efficacy and safety of cabozantinib plus atezolizumab or cabozantinib alone in advanced NSCLC previously treated with an immune checkpoint inhibitor (ICI). Methods: COSMIC-021 (NCT03170960) is a phase 1b, multicenter study
Externí odkaz:
https://doaj.org/article/6812448f29344fa6a786793805d199c0
Autor:
A.J. Piper-Vallillo, MD, Julia K. Rotow, MD, Jacqueline V. Aredo, MD, Khvaramze Shaverdashvili, MD, PhD, Jia Luo, MD, Jennifer W. Carlisle, MD, Hatim Husain, MD, Alona Muzikansky, MA, Rebecca S. Heist, MD, Deepa Rangachari, MD, Suresh S. Ramalingam, MD, Heather A. Wakelee, MD, Helena A. Yu, MD, Lecia V. Sequist, MD, Joshua M. Bauml, MD, Joel W. Neal, MD, PhD, Zofia Piotrowska, MD, MHS
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 6, Pp 100328- (2022)
Introduction: This multicenter review evaluated the efficacy and safety of osimertinib dose escalation for central nervous system (CNS) progression developing on osimertinib 80 mg in EGFR-mutant NSCLC. Methods: Retrospective review identified 105 pat
Externí odkaz:
https://doaj.org/article/a0defd29b0c2448591b1a44036d37442
Autor:
Sai-Hong Ignatius Ou, MD, Huamao M. Lin, PhD, MBA, Jin-Liern Hong, PhD, Yu Yin, MS, MPH, Shu Jin, MS, Jianchang Lin, PhD, Minal Mehta, MBBS, Danny Nguyen, MD, Joel W. Neal, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 10, Pp 100558- (2023)
Introduction: This study describes treatment patterns and outcomes in patients with NSCLC with EGFR exon 20 insertions (EGFRex20ins) in the United States. Methods: The Flatiron Health electronic health record database was used to select three cohorts
Externí odkaz:
https://doaj.org/article/a85d4cc4ba7e4e79b72ec1af541ad695
Autor:
Thomas Yang Sun, MD, MHS, Brandon Nguyen, BA, Simon B. Chen, MD, Yasodha Natkunam, MD, PhD, Sukhmani Padda, MD, Matt van de Rijn, MD, Robert West, MD, PhD, Joel W. Neal, MD, PhD, Heather Wakelee, MD, Jonathan W. Riess, MD, MS
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 4, Pp 100498- (2023)
Introduction: CD47 is a tumor antigen that inhibits phagocytosis leading to immune evasion. Anti-CD47 therapy is a promising new immunotherapy across numerous tumor types, but it has not been tested in thymic epithelial tumors (TETs): thymomas and th
Externí odkaz:
https://doaj.org/article/30e41af60d4241beac6dc7f512ddccc4
Autor:
Jingran Ji, MD, Jacqueline V. Aredo, MD, MS, Andrew Piper-Vallillo, MD, Laura Huppert, MD, Julia K. Rotow, MD, Hatim Husain, MD, Susan Stewart, PhD, Rosemary Cobb, BS, Heather A. Wakelee, MD, Collin M. Blakely, MD, PhD, Melisa L. Wong, MD, MAS, Matthew A. Gubens, MD, MS, Mohammad H. Madani, MD, Subba R. Digumarthy, MD, Caroline McCoach, MD, PhD, Zofia Piotrowska, MD, MHS, Joel W. Neal, MD, PhD, Jonathan W. Riess, MD, MS
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 3, Pp 100459- (2023)
Introduction: EGFR mutations drive a subset of NSCLC. Patients harboring the common EGFR mutations, deletion of exon 19 and L858R, respond well to osimertinib, a third-generation tyrosine kinase inhibitor. Nevertheless, the effect of osimertinib on N
Externí odkaz:
https://doaj.org/article/0cd8922ebf5946adba6b0fb71a9d9100